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Locally advanced (stage III or IV) squamous cell carcinoma of the head and neck (SCCHN) often requires multimodal
treatment, consisting of a combination of surgery, radiation, and/or systemic therapy, namely chemotherapy or
targeted agents. The expression of the epidermal growth factor receptor (EGFR) has been detected in more than
90% of all cases of SCCHN and has been correlated with decreased survival rates, resistance to radiotherapy,
loco-regional treatment failure, and increased rates of distant metastases. This paper discusses several strategies
aimed at targeting EGFR in combination with radiation. Until now, cetuximab, an anti-EGFR monoclonal antibody, is
the only targeted agent that has been shown to improve overall survival in combination with radiation therapy.
However, considering that there are multiple mechanisms of primary and acquired resistance to EGFR inhibitors, we
focused on dissecting molecular pathways of EGFR inhibition to find alternative or complementary strategies for
increasing tumour responsiveness. We suggest that the combination of treatments targeting the EGFR pathway and
drugs aimed at increasing immune responses represent a promising approach that deserves to be further explored.Background
Squamous cell carcinoma of the head and neck
(SCCHN) represents approximately 90% of all cancer
arising in the head and neck area [1] and represents the
sixth most common type of cancer, diagnosed in over
600,000 patients worldwide every year [2]. Prognostic
factors in SCCHN are limited, except for the recognized
positive role of human papilloma virus (HPV), mainly in
association with oropharyngeal cancer. In this regard,
SCCHN can be broadly divided into HPV-negative,
more frequently associated with alcohol and tobacco
consumption, and those where HPV is a causal factor
[3]. Treatment choices are mainly based on the primary
tumour site, TNM staging, and performance status.
Advanced disease (stage III or IV) often requires multi-
modal treatment, consisting of a combination of surgery,
radiation and/or chemotherapy [3]. When combined with
radiation, systemic chemotherapy is most frequently based
on platinum compounds, which have shown to yield the
greatest benefits in combined treatment strategies [4].
On the quest for a better understanding of the mo-
lecular biology of SCCHN, researchers have focused on* Correspondence: paolo.bossi@istitutotumori.mi.it
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In fact, the expression of the EGFR is detected in more
than 90% of all cases of SCCHN and has been correlated
with decreased survival rates, resistance to radiotherapy,
loco-regional treatment failure, and increased rates of
distant metastases [5]. Based on clinical relevance, the
EGFR antibody cetuximab is the only monoclonal anti-
body (mab) to have been approved by the US Food and
Drug Administration and the European Medical Agency,
for use in combination with radiation in cases of locally
advanced diseases and added to platinum-based chemo-
therapy in cases of recurrent-metastatic SCCHN [6, 7].
The aim of this paper is to review clinical trials and
translational studies that pursue therapeutic approaches
based on radiotherapy plus EGFR inhibition and illus-
trate their benefits, suggesting that further work should
be done in this direction.
Molecular mechanisms of EGFR blockade plus radiation
and resistance pathways
Since EGFR is an established target in SCCHN treat-
ment, several molecular mechanisms may explain the
synergistic effect of EGFR-targeted therapies and radi-
ation. In fact, the combination of EGFR blockade and
radiation exploits three distinct roles that the EGFRle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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liferation, the activation of pro-survival pathways, and
DNA repair [8]. What follows is a brief explanation of
these functions and of the mechanisms of resistance to
anti-EGFR therapies.
Enhanced cell proliferation
The accelerated proliferation of tumour cells during
radiotherapy is one reason for loco-regional therapies
failure. Shortening overall treatment time makes tumour
control more likely, so that tumour cells repopulation
between radiotherapy fractions could be more difficult.
The accelerated proliferation rate could result from the
activation of EGFR in response to ionising radiation,
which would indicate that EGFR-related signalling is in-
volved in the proliferative response to radiotherapy,
thereby enhancing survival probabilities [9].
Activation of pro-survival pathways
Resistance to radiotherapy could also be caused by
EGFR downstream effectors known to activate pro-
survival pathways.
In this regard, the role of cetuximab as a “radiosensiti-
zer” could be explained by its capacity to partially inhibit
STAT-3 (the signal transducer and activator of transcrip-
tion 3), an apoptosis protection mediator.
Focusing specifically on SCCHN, prior research has
found over-expression of mTOR and genomic alteration
in the PI3K/AKT signalling pathway to be associated with
decreased overall survival rates [10]. In addition, pAKT
expression has been proven to be a putative biomarker
predictor of response to cetuximab-based chemotherapy
[11]. According to a 2015 study by Schuettler et al., irradi-
ation induces the phosphorylation of AKT, p38 MAPK,
and ERK [12]. The combined activation of these pathways
has been proven to cause inactivation of GSK3β kinase,
resulting in enhanced tumour cell migration. Further-
more, as shown by Mishra et al., inhibition of GSK3β acti-
vates wnt-/β-catenin signalling, which has been linked to
enhanced cell migration in oral squamous carcinoma cell
lines [13]. This means that the specific inhibition of even
one of the EGFR’s downstream pathways is sufficient to
restore GSK3β activity and reduce radiation-induced mi-
gration in SCCHN.
DNA repair
EGFR is known as a cell surface receptor, but resist-
ance to radiation therapy has also been related to nu-
clear EGFR expression, an isoform that plays an
important role in gene expression (such as cyclin D1,
COX-2, c-Myc and aurora kinase A) and in DNA re-
pair [14]. Radiation promotes the internalization and
transport of EGFR by caveolin-1, leading to the activa-
tion of DNA-PK (a vital kinase for joining repair) inresponse to DNA damage. In this respect, researchers
have shown that inhibition of EGFR with cetuximab
attenuates EGFR nuclear import and suppresses DNA-
PK activity [8].Promising trials and next steps to overcome resistance
In a recent study, Bonner and colleagues explored the
combined dual inhibition of EGFR and JAK–STAT-3
with and without radiation in human SCCHN cell lines.
They found that combining cetuximab and radiation
therapy with adjunct treatment that targets the JAK1 en-
hances the anti-proliferative, apoptotic, and radio-
sensitizing effects of radiation, causing an increase of
unrepaired radiation-induced DNA double-strand breaks
when cells are exposed to both drugs [15].
In addition, clinical evidence also shows that the EGFR
blockade activates the MET pathway (as a compensatory
mechanism, thus causing resistance to EGFR inhibitors.
This further supports the strategy that aimed at dual
blocking of HGF/MET and EGFR pathways [16].
Another mechanism that supports the innovative
strategy of integrating dual blocking with a combined
therapeutic approach is the cross-talk between EGFR
and VEGF survival pathways. Several clinical studies
have yielded positive results when using a combination
of bevacizumab, cetuximab, and chemotherapy in
addition to radiation or when adding bevacizumab to
the combination of erlotinib, chemotherapy, and radi-
ation [17–19]. Further exploration of these combined
strategies and their safety profiles thus seems like a
promising direction to pursue.
Moreover, there is also evidence of the Hedgehog
pathway being relevant to a novel cetuximab resistance
mechanism involving epithelial to mesenchymal transi-
tion (EMT). Specifically, a recent phase I trial has shown
that cetuximab in combination with IPI-926, a hedgehog
pathway inhibitor, yields anti-tumour activity with well-
tolerated toxicities [20].
Inhibition of EGFR: monoclonal antibodies and tyrosine
kinase inhibitors
There are two main ways to inhibit EGFR signalling
pathways: monoclonal antibodies targeting EGFR, which
directly interfere with the ligand receptor, and tyrosine
kinase inhibitors, which block the intracellular domain
with tyrosine kinase activity [1].
Monoclonal antibodies
When speaking of SCCHN, the most investigated
monoclonal antibodies that specifically bind to EGFR
are cetuximab, panitumumab, nimotuzumab, and zalu-
tumumab. Table 1 summarizes the main trials in locor-
egionally advanced SCCHN.
Table 1 Main trials with monoclonal antibodies associated with radiotherapy in locally advanced SCCHN
Study Treatment Efficacy Toxicities
LRC PFS OS RR G3-4 dermatitis G3-4 mucositis G3-4 dysphagia
Bonner et al. [6, 21] RT 5-yr 36.4% 18% 52%
RT + cetuximab 5-yr 45.6% 23% 56%
Fury MG et al. [17] cet + bevacizumab
+ CDDP + RT
2-yr 88.5% 2-yr 92.8% 3% 3%
Lefebvre JL et al. [22] TPF→ RT + CDDP vs 92% 26% 43%
TPF→ RT + cet 89% 57% 43%
Mesia R et al. [25] RT + cet vs 1-yr 47% 2%
RT + cet + 12 weeks maint 1-yr 59% 7%
2-yr similar
Egloff AM et al. [47] Cet + CDDP + 2-yr 47% 2-yr 66% 66.7% 26% 55% 46%
RT + cet maint
Ang KK et al. [26] RT + CDDP vs 3-yr 61.2% 3-yr 72.9% 33%
RT + CDDP + cet 3-yr 58.9% 3-yr 75.8% 43%
Mesia R et al. [28] RT + CDDP vs 2-yr 68% 24% 27%
RT + CDDP + PMab 2-yr 61% 55% 40%
Giralt J et al. [29] RT + PMab vs 2-yr 51% 40% 42%
RT + CDDP 2-yr 61% 32% 40%
Siu LL et al. [30] RT + CDDP vs 2-yr 73% 2-yr 85%
RT + Pmab 2-yr 76% 2-yr 88%
Reddy BK et al. [31] RT + CDDP + NMab 5-yr 57% 11% 4%
CDDP + RT 5-yr 26% 5% 1%
RT + NMab 5-yr 39% 10% 2%
RT 5-yr 26% 16%
Eriksen JG et al. [33] RT+ CDDP + nimo + ZMab 4-yr 71% 29%
Vs RT + CDDP + nimo 4-yr 73%
Abbreviations: Cet cetuximab, PMab panitumumab, NMab nimotuzumab, ZMab zalutumumab, nimo nimorazole, CDDP cisplatin, CHT chemotherapy, RT
radiotherapy, LRC locoregional control, OS Overall Survival, RR response rate, PFS Progression-Free Survival, RR response rate, G grade
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vestigated and until now has been deployed in various
treatment strategies based on radiation therapy (which
we discuss in detail below).
The pivotal study by Bonner et al., already mentioned
above and discussed in several journals, showed that in
cases of locoregionally advanced SCCHN, patients
treated with a combination of cetuximab plus radio-
therapy had an advantage in 5-year overall survival
(OS), compared to those threated by radiation alone
(5-year OS 45.6% vs. 36.4%). In addition, overall sur-
vival improved significantly if the patient developed
rashes of grade-2 severity [6, 21]. Cetuximab plus radi-
ation has also been investigated after induction chemo-
therapy (docetaxel, cisplatin and 5-fluorouracil, TPF).
For instance, the Tremplin study, which explored a
new combination strategy for organ preservation in
cases of laryngeal and hypopharyngeal cancer, involved
TPF followed by radiation in combination with eithercisplatin or cetuximab. The study proved that there was
no difference in disease control and in overall survival
between the two combinations. The only differences
found were that cisplatin yielded higher local control
and that only the cetuximab treated group required sal-
vage surgery [22]. A Spanish trial investigated the same
strategy in cases of locally advanced SCCHN, most of
which HPV negative. The results showed a trend of
better PFS (HR 1.20) and OS (HR 1.17) when using
cisplatin in addition to radiation after induction TPF
[23]. As expected, the two drugs yielded a very differ-
ent toxicity profile: cetuximab was associated with
more mucosal and skin toxicity and cisplatin with
greater nephrotoxicity.
Another important trial study, known as GORTEC
2007–02, compared the use of chemoradiation (with car-
boplatin and 5FU) in concurrence with induction TPF
followed by radiation with cetuximab, in locally ad-
vanced clinical stage N2b-N3 SCCHN and found no
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that concurrent chemoradiation (even if not performed
with cisplatin) remains the best treatment also with a
high burden of nodal disease [24].
Another randomized phase II trial, instead, explored
an adjuvant treatment strategy that consisted of admin-
istering cetuximab for twelve weeks after use in com-
bination with radiotherapy. Despite favourable results
for locoregional control after 1 year, no difference was
observed at the 2-year stage [25].
There is also a number of trials that investigate the as-
sociation of cetuximab to cisplatin and radiation. The
largest of these preliminary studies, the RTOG 0522,
shows that cetuximab plus cisplatin, in comparison to
cisplatin alone, yields increased acute toxicities, more
frequent radiotherapy interruption, and no survival ben-
efits [26]. Recently, the GORTEC 2007–01 phase III ran-
domized trial showed that the addition of concomitant
chemotherapy to cetuximab-based radiotherapy mark-
edly improved progression-free survival and locoregional
control, with a non-significant gain in survival [27]. This
study targeted patients with limited locally advanced dis-
ease (N0-N2a), mainly HPV negative (65% of the pa-
tients had oropharyngeal cancer, but only 20% of them
were p16 positive). Results showed that in this popula-
tion the additional use of chemotherapy produced better
results than treatment based just on cetuximab plus
radiation.
Moving on to other monoclonal antibodies, an im-
portant reference is the set of CONCERT trials (CON-
comitant Chemotherapy and/or EGFR inhibition with
Radiation Therapy), which investigated the use of
panitumumab in addition or in substitution to
cisplatin-based chemotherapy and in combination
with radiation, for the treatment of locally advanced
SCCHN. For each trial, the results showed that this
strategy does not yield significant benefits [28, 29].
Specifically, the CONCERT-1 trial concluded that the
addition of panitumumab to chemoradiation not only
did not yield any superior efficacy, but led to an in-
crease in acute toxicity. Instead, the CONCERT-2 trial
concluded that panitumumab does not constitute a
viable substitute to cisplatin, in light of an inferior pri-
mary endpoint of locoregional control at the 2-year
stage (51% with panitumumab vs. 61% with cisplatin).
In a recent study, instead, panitumumab was added as
radiosensitizer to accelerated fractionation radiation
and compared to standard fractionation radiation in
combination with cisplatin [30]. The strategy resulted
in a higher than expected survival probability for the
entire group, but this is explained by the fact that the
test population was mainly constituted by patients af-
fected by oropharyngeal cancer (81%), most of whom
were p16 positive. Aside from this, the study showedthat treatment with panitumumab is not more effect-
ive than chemotherapy, although the altered fraction-
ation scheme did not allow for a formal test of non-
inferiority. Overall, the data clearly demonstrates that
panitumumab cannot and should not replace cisplatin
in combined treatment with radiotherapy.
Finally, as regards nimotuzumab, in a phase-II trial
the use of the monoclonal antibody in addition to che-
moradiation or radiation seemed to provide long-term
survival benefits [31]. Another phase II trial enrolled
106 patients with unresectable SCCHN and random-
ized them for treatment with either radiotherapy alone
or with radiotherapy in combination with nimotuzumab
and showed a significant complete response rate im-
provement in the group of patients treated with nimo-
tuzumab [32]. Instead, in the case of zalutumumab, the
Danish Head and Neck Cancer Group (DAHANCA)
inquired whether the addition of the monoclonal anti-
body during radiotherapy could improve outcome in
patients with locally advanced SCCHN and found no
difference in locoregional control [33].
Tyrosine kinase inhibitors
Several EGFR tyrosine kinase inhibitors (TKI), such as
lapatinib, gefitinib and erlotinib, have been investi-
gated in SCCHN concurrently with radiation, as
shown in Table 2. According to a phase III trial, there
are no survival benefits associated with lapatinib, a
small-molecule inhibitor of EGFR and of the human
epidermal growth factor receptor 2 (HER2, ErbB2),
neither when paired with chemoradiation nor when
used as a maintenance monotherapy in patients with
high-risk surgically-treated SCCHN [34].
Another phase II trial by Martins et al. randomly se-
lected 204 patients to receive radiotherapy plus cis-
platin, with or without the addition of erlotinib. Even if
well tolerated, erlotinib failed to produce a significant
improvement in both the complete response rate and
in progression-free survival [35]. Hainsworth et al.
evaluated the feasibility and efficacy of adding both
bevacizumab and erlotinib to concurrent chemoradia-
tion (CRT) as a first-line treatment in locally advanced
SCCHN. The 3-year progression-free survival rate and
the overall survival rate for the entire group were re-
spectively 71% and 85% and the most frequent severe
toxicity was grade 3/4 mucosal toxicity [19]. Several
other studies investigated the safety and efficacy of er-
lotinib combined with concurrent chemoradiation, but
their sample size was too small to allow for any signifi-
cant conclusions [18, 36].
There is also evidence against potential benefits to be
gained from gefitinib. Specifically, a randomized phase II
trial based on 226 subjects tested the differences be-
tween treating patients with gefitinib 250 mg/day,
Table 2 Main trials with tyrosine kinase inhibitors associated with radiotherapy in locally advanced SCCHN
Study Treatment Efficacy Toxicities






Harrington K et al.
[34]
RT + CDDP vs 5-yr
57.3%
RT + CDDP+ lapatinib 5-yr
56.6%
Martins RG et al.
[35]
CDDP + RT vs No
difference
40% 2%
CDDP + RT+ erlotinib 52% 13%
Hainsworth JD et al.
[19]
CBDCA + Tax + 5FU + beva
→ RT+ Tax + beva + erlotinib
3-yr 71% 3-yr 82% 88%
Yoo DS et al.
[18]
Beva + erlotinib + CDDP + RT 3-yr
85%
3-yr 82% 3-yr 86% 48% 28%





Gregoire V et al.
[37]
CDDP + RT vs 2-yr
33.6%
36% 13%





Cohen EE et al.
[38]
FU + hydroxyurea + RT +
gefitinib + 2-years maint
gefitinib
4-yr 72% 4-yr 74% 33% 55%
Hainsworth JD et al.
[48]
CBDCA + Doc + 5FU +
gefitinib
followed by RT + Doc +
gefitinib
and 2-years gefitinib
3-yr 41% 3-yr 54% 27%
Rodriguez CP et al.
[49]
RT + CDDP + 5FU + gefitinib
+2-years gefitinib
3-yr 71% 87%
Abbreviations: CBDCA carboplatin, Tax paclitaxel, Doc docetaxel, 5FU 5-fluorouracil, CDDP cisplatin, beva bevacizumab, RT radiotherapy, LDCR local disease control
rate, LRC locoregional control, OS Overall Survival, DFS Disease Free Survival, PFS Progression-Free Survival, RR response rate, G grade, maint maintenance
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tured in two phases: a concomitant phase (gefitinib or
placebo with chemoradiation) and a maintenance phase
(gefitinib or placebo alone). The investigators concluded
that treatment with gefitinib did not improve 2-year
loco-regional control compared to placebo, neither
when given concomitantly with chemoradiation nor as
maintenance therapy [37]. Another phase II study in-
vestigated the feasibility of administering gefitinib in
concomitance with chemoradiation and then alone as
maintenance therapy for two years. Gefitinib proved to
be well tolerated in the adjuvant phase, but associated
with a high incidence of treatment-related death during
the first concurrent phase [38].
Finally, the LUX-Head and Neck 2 trial, a phase III
study that is still in progress, might be able to say a de-
finitive word on the role of afatinib, an irreversible
ERbB-family blocker. Specifically, the study aims to as-
sess the use of afatinib versus placebo as an adjuvant
treatment following concurrent chemoradiation in pri-
mary unresected locoregionally-advanced SCCHN, with
disease-free survival as a primary endpoint [39].The role of EGFR inhibition in HPV-positive versus
HPV-negative SCCHN
HPV-positive types of SCCHN are driven by the integra-
tion of HPV DNA into the host genome and the activa-
tion of specific and consistent molecular regulators,
including p16INK4, representing a distinct SCCHN entity
[3]. Analyses of 279 cases of SCCHN by The Cancer
Genome Atlas identified p53 mutations in 84% of HPV-
negative tumours and only in 3% of HPV-positive
tumours, supporting the thesis that smoking and alco-
hol related cases of SCCHN are associated with near-
universal loss of p53 function through its mutation and
with CDKN2A inactivation. On the other hand, HPV-
positive cancers cause p53 degradation through the
binding of the E6 protein with the ubiquitin ligase E6-
associated protein (E6AP) to the p53 of host cells.
However, this mechanism of p53 alteration explains
only in part the different chemo- and radio-sensitivity
of HPV-positive versus HPV-negative cancers.
Further investigation in this direction is represented
by a set of preclinical studies that tested interesting hy-
pothesis for radio-sensitization of HPV-positive cancer
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deregulation and the down-regulation of HPV E6 and E7
proteins serve to promote the enhanced sensitivity of
HPV+ SCCHN cells to simultaneous radio-chemotherapy
[40]. In this regard, it is worth noting that cetuximab has
been shown to inhibit the growth of E6- and E7-
expressing tumours grafted in NOD-SCID mice, thus
offering further evidence of the combined effect of
radiotherapy and anti-EGFR treatment in HPV-positive
cancers [41].
Other significant findings from a clinical point of view
are associated to a study by Rosenthal et al. that evalu-
ated the association between p16 and HPV expression
by carrying out a retrospective analysis of the phase III
IMCL-9815 study, which compared the effects of com-
bined treatment by radiotherapy plus cetuximab versus
treatment by radiotherapy alone. The study confirmed
the prognostic role of p16 in both groups of patients,
but was not able to assess p16 as a predictive factor for
response to cetuximab. However, it should be noted that
the magnitude of benefits obtained by the adjunct use of
cetuximab were higher in p16-positive tumours than to
p16-negative ones [42].
Ongoing trials
There are also several trials that are investigating the
possibility of de-escalating treatment intensity among
patients affected by HPV-positive oropharyngeal cancer,
by using cetuximab as a radiosensitizer and comparing
the efficacy of cetuximab versus cisplatin concurrently
with radiation (RTOG 1016, De-ESCALaTE and TROG
12.01). The results of these trials will be especially im-
portant since, now, there are no biological markers in
HPV-positive SCCHN known to have a predictive value
for response to EGFR inhibition.
New perspectives: anti-EGFR + immunotherapy
The immunotherapeutic approach is gaining more and
more consensus in the treatment of cancer. As regards
SCCHN patients in particular, there are several ongoing
trials that are producing encouraging results so far, with
a response rate of about 20% in the heavily pre-treated
setting of second-line treatment for relapsed-metastatic
patients [43–45] and long-lasting responses in a number
of cases, something that was extremely rare in previous
trials involving treatment with chemotherapy and cetuxi-
mab [46].
This evidence is of importance, since the SCCHN
population is known to have reduced immunoreactivity
towards cancer, as proven by low absolute lymphocyte
counts, an impaired natural killer-cell pool, a poor
antigen-presenting function, the impairment of tumour-
infiltrating T lymphocytes, and suppressive regulatory T
cells that secrete suppressive cytokines such as TGF-βand IL-10 [3–55]. Some researchers suggest that the lack
of immunological control in SCCHN may also be driven
by the expression of immune-inhibitory checkpoints,
mainly the cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) and the programmed cell death protein 1
(PD-1), which normally regulate the ongoing immune
response to prevent damage to healthy tissues [56–58].
Furthermore, SCCHN associated with alcohol and to-
bacco consumption is characterized by a high number of
gene mutations [59] and, as we know, the mutational
load is one of the genetic cancer factor influencing the
possible restoration of an effective immune response. In
light of these premises, SCCHN seems like good candi-
date for studies aimed at investigating the pursuit of im-
munotherapeutic strategies in combination with existing
therapies of known value [60].
Returning to the line of inquiry focused on cetuximab,
since the antibody works not only by blocking EGFR-
related downstream pathways, but also by mediating the
antibody-dependent cellular cytotoxicity (ADCC) of NK
cells [61] as well as complement-mediated cytotoxicity
[62] and adaptive immunity [63], it may be worthwhile
to invest in the pursuit of EGFR therapies that also tar-
get secondary immune responses [64].
Moreover, since the immune response to cetuximab
alone is limited, as witnessed by the limited rate of long-
term responders, we suggest that clinical research should
focus especially on combined treatments aimed at over-
coming the immune evasion to anti-EGFR therapy. In
SCCHN, the constitutive activation of STAT3 is re-
sponsible for tumour-immune evasion, producing
immunosuppressive mediators and creating an immune
tolerant microenvironment [65], In light of this, EGFR-
independent STAT3 activation could contribute to a re-
duced response to cetuximab. If this were the case, the
blockade of both targets might constitute a new thera-
peutic strategy [66]. Moreover, as shown by Pollack
et al., EGFR-blockers may overcome the inhibitory
effect of EGFR-signalling by increasing MHC expres-
sion [67]. We thus also suggest that the overall efficacy
of EGFR inhibitor-targeted therapy in SCCHN patients
could be enhanced by the addition of T-cell-based im-
munotherapy. A study by Kumai et al. offers promising
evidence in this respect, showing that the EGFR875–
889 peptide induced effective anti-tumor CD4 T-cell
responses against cancer that expressed EGFR. The
authors thus suggest that the peptide could serve as an
effective cross-reacting epitope, inducing responses to
other HER family members and to the c-Met antigen
[68]. Another encouraging phase Ib study aimed at
evaluating the effectiveness of using cetuximab with
motolimod, a small-molecule TLR-8 agonist that acti-
vates myeloid dendritic cells, monocytes, and natural
killer cells. Preliminary results show a response rate of
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tients [69]. However, the results of a recently presented
randomized trial showed that adding motolimod to
standard platinum, 5-fluorouracil and cetuximab ther-
apy for metastatic SCCHN resulted in no benefit in OS
and PFS [70]. Finally, another reason for pursuing com-
bined approaches is that cetuximab monotherapy pro-
motes Tregs expansion, which in turn increases
immune-suppression in the tumoral microenvironment,
particularly towards NK cell activity [71]. The expres-
sion of CTLA-4 on Tregs thus motivates a new thera-
peutic approach based on a combination of cetuximab
and ipilimumab, aimed at increasing immune response
against the tumour [72]. This combined treatment is
currently undergoing phase Ib testing along with radi-
ation, in stage III-IV SCCHN (NCT01935921).
Conclusions
The use of radiation therapy in combination with cetuxi-
mab, an anti-EGFR monoclonal antibody, has been
shown to improve overall survival in SCCHN patients.
However, since clinical studies have shown that not all
tumours are sensitive to EGFR inhibition and that others
may develop acquired resistance, we suggest that a bet-
ter understanding of the molecular mechanisms involved
in EGFR-resistance is crucial to developing optimal
therapeutic approaches. We believe that clinical research
should focus on the use of combination or sequential
targeted therapies that involve strategies aimed at en-
hancing immune response.
Abbreviation
ADCC: Antibody-dependent cellular cytotoxicity; CRT: Chemoradiation;
CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; EGFR: Epidermal
growth factor receptor; EMT: Epithelial to mesenchymal transition;
HER2: Human epidermal growth factor receptor 2; HPV: Human papilloma
virus; OS: Overall survival; PD-1: Programmed cell death protein 1;
SCCHN: Squamous cell carcinoma of head and neck; TKI: Tyrosine kinase
inhibitors; TPF: Docetaxel, cisplatin and 5-fluorouracil.
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